L’Oreal aims for La Roche Posay site buyout
L’Oréal has submitted to the shareholders of Holding STRP (Société des Thermes de La Roche-Posay) an irrevocable offer for the acquisition of the totality of the shares of the company.
The beauty player is keen to take full control of the skin care brand which it situates as part of its Active Beauty division, for brands which are created with and endorsed by dermatologists, pediatricians and other physicians.
The project of acquisition planned by L’Oréal foresees the prior carve out of the hotel business to the current shareholders of Holding STRP, and the attribution of exclusive negotiation rights to L'Oréal, the company says.
Spotlight on La Roche-Posay
Société des Thermes de La Roche-Posay is the first thermal station in Europe exclusively dedicated to treating dermatological diseases. It was created in 1921.
The thermal water of La Roche-Posay has therapeutic anti-inflammatory, healing and soothing properties to treat skin diseases (eczema, psoriasis, burn scars and cutaneous side effects of cancer treatments).
In 2017, more than 7500 patients have benefited from the thermal activity, generating 3.6 million euros of sales.
Recommended by over 90,000 dermatologists worldwide, La Roche-Posay creates skincare for sensitive skin, formulated with thermal water. First dermo-cosmetic brand worldwide, its key product ranges are: Lipikar (dry skin), Anthélios (photoprotection), Effaclar (acne), Tolériane (sensitive skin) and Cicaplast (skin repair).
Laetitia Toupet, International General Manager of La Roche-Posay, said: “this acquisition project will enable us to sustain and reinforce the dermatologic position of La Roche-Posay by developing the existing indications and making the thermal station a flagship for the brand.”
This project will be submitted for consultation to employee representatives and should be completed within the following months.
